REMARKS

Reconsideration of this application, as amended, is respectfully requested.

The Applicants wish to draw the Examiner's attention to the Applicants' related copending applications and issued patents (see updated Appendix A) directed to nanoparticles and methods of preparation and use thereof.

Further to the Applicant's prior response filed on June 18, 2003, the Applicants note that the Examiner still did not return executed copies of the PTO 1449 forms for the 7th Supp. Information disclosure statement filed on May 1, 2003. The Applicants request that the Examiner fully execute the PTO 1449 form for the 7th Supp. IDS and return a copy of the same to the undersigned representative. A copy of the 7th Supplemental IDSs, associated PTO 1449 form, and PTO stamped postcard acknowledging receipt of the IDS, PTO 1449 form and references are attached. The Examiner is requested to contact the undersigned representative if the Examiner would like to have another copy of the references.

Claims 237-265 and 433-446 were pending in this application. Without prejudice or disclaimer, claims 237-265 and 438 were cancelled and claims 433, 439 and 444 were amended in order to correct claim dependencies and to expedite the allowance of this application as the Examiner had indicated that claims 438-446 would be allowable if placed into independent format. Claim 433 was amended to incorporate the subject matter of cancelled claim 438. This amendment does not constitute new matter.

Turning to the office action, claims 238-242, and 433-437 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 237, 239-242 of allowed co-pending application No. 09/976,577. A terminal disclaimer is attached. Accordingly, the Applicants submit that the obviousness-type double patenting rejection has been overcome.

Claims 243-265 have been provisionally rejected under 35 U.S.C. section 101 as claiming the same invention as claims 243-265 of co-pending application No. 09/976,618. Since claims 243-265 in the instant application had been cancelled, the Applicants respectfully submit that the double patenting (same invention) rejection no longer applies.

Claims 237, 241-247, 251 and 252 stand rejected under 35 U.S.C. section 102(e) as being anticipated by, or in the alternative, under 35 USC section 103(a) as being obvious over

Yguerabide (U.S. Patent No. 6,214,560)("Yguerabide"). The Applicants respectfully traverse this rejection and submit, without commenting on the merits or lack thereof of the rejection, that the rejection is most in light of the present amendment which cancelled the aforementioned claims.

In conclusion, the Applicants respectfully submit that the claims in this application are in allowable condition and request a Notice to this effect.

Reconsideration of this application is respectfully requested and a favorable determination is earnestly solicited. The Examiner is invited to contact the undersigned representative if the Examiner believes that this would be helpful in expediting the prosecution of this application.

Dated:

Respectfully submitted,

Emily Miao

Reg. No. 35,285

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive Chicago, IL 60606

Telephone: 312-913-0001 Facsimile: 312-913-0001



APPENDIX A

A TRA	DEMAR	ENDIA A	:	DECENTER
ATTY	Serial No./		1	RECEIVED
Case No.	Filing Date	Inventors/Title	Status	MADIA
00-653-A	U.S. 09/927,777 Filed 8/10/01	Mirkin, Letsinger, Mucic, Storhoff, Elghanian, Taton, Garamella, Li, Park/ NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFORE	ALLOWED	MAR 1 0 2004
00-713-B1	09/923,625 Filed 8/7/01	Mirkin, Letsinger, Mucic, Storhoff, Elghanian/ NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFOR	ALLOWED	
00-713-С	09/344,667, filed 6/25/99	Mirkin, Letsinger, Mucic, Storhoff, Elghanian/ NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFORE	U.S. Patent No. 6,361,944, issued 3/26/02	
00-713-I	U.S.S.N 09/603,830 Filed 6/26/00	Mirkin, Letsinger, Mucic, Storhoff, Elghanian, Taton; NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFOR	U.S. Patent No. 6,506,564, issued 1/14/03	
00-713-I-1	09/961,949 9/20/01	Mirkin, Letsinger, Mucic, Storhoff, Elghanian, Taton;	U.S. Patent No. 6,582,921, issued June 24, 2003	

ATTY	Serial No./		1 ago
Case No.	Filing Date	Inventors/Title	Status
		NANOPARTICLES	
		HAVING	
		OLIGONUCLEOTI	
		DES ATTACHED	
		THERETO AND	
		USES THEREFOR	
00-713-I-2	09/957,318	See 00-713-I-1	ALLOWED
	9/20/01		
00-713-I-3	09/957,313	See 00-713-I-1	U.S. Patent No.
	9/20/01		6,645,721, issued
			11/11/03
00-713-I-4	09/966,491	See 00-713-I-1	U.S. Patent No.
	9/28/01		6,610,491, issued
			August 26, 2003
00-713-I-5	09/966,312	See 00-713-I-1	U.S. Patent No.
	9/28/01		6,673,548, issued
			January 6, 2004
00-713-I-6	09/967,409	See 00-713-I-1	ALLOWED
	9/28/01		
00-713-I-7	09/974,500	See 00-713-I-1	ALLOWED
	10/10/01		
00-713-I-8	09/974,007	See 00-713-I-1	PENDING
	10/10/01		
00-713-I-9	09/973,638	See 00-713-I-1	PENDING
	10/10/01		
00-713-I-	09/973,788	See 00-713-I-1	ALLOWED
10	10/10/01		
00-713-I-	09/975,062	See 00-713-I-1	U.S. Patent No.
11	10/11/01		6,677,122, issued
			January 13, 2004
00-713-I-	09/975,376	See 00-713-I-1	PENDING
12	10/11/01		
00-713-I-	09/975,384	See 00-713-I-1	PENDING
13	10/11/01		

ATTY	Serial No./		1 ug
Case No.	Filing Date	Inventors/Title	Status
00-713-I-	09/975,498	See 00-713-I-1	ALLOWED
14	10/11/01		
00-713-I-	09/975,059	See 00-713-I-1	ALLOWED
15	11/11/01	·	
00-713-I-	09/976,601	See 00-713-I-1	PENDING
16	10/12/01		
00-713-I-	09/976,968	See 00-713-I-1	PENDING
17	10/12/01		
00-713-I-	09/976,971	See 00-713-I-1	U.S. Patent No.
18	10/12/01		6,682,895, issued
			1/27/04
00-713-I-	09/976,863	See 00-713-I-1	PENDING
19	10/12/01		
00-713-I-	09/976,577	See 00-713-I-1	ALLOWED
20	10/12/01		
00-713-I-	09/976,618	See 00-713-I-1	ALLOWED
21	10/12/01		
00-713-I-	09/981,344	See 00-713-I-1	ALLOWED
22	10/15/01		
00-713-I-	09/976,900	See 00-713-I-1	PENDING
23	10/12/01		
00-713-I-	09/976,617	See 00-713-I-1	ALLOWED
24	10/12/01		
00-713-I-	09/976,378	See 00-713-I-1	PENDING
25	10/12/01		
00-713-i-	10/410,324	See 00-713-I-1	PENDING
26	04/10/03		
00-713-L	U.S.S.N.	Mirkin, Letsinger,	U.S. Patent No.
	09/693,005	Mucic, Storhoff,	6,495,324, issued
	Filed 10/20/00	Elghanian/	12/17/02
		NANOPARTICLES	
		HAVING	
		OLIGONUCLEOTI	

ATTY	Serial No./		T ag
Case No.	Filing Date	Inventors/Title	Status
		DES ATTACHED THERETO AND USES THEREFORE	
00-713-М	U.S.S.N. 09/693,352 Filed 10/20/00	Mirkin, Letsinger, Mucic, Storhoff, Elghanian/ NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFORE	U.S. Patent No. 6,417,340, issued 7/9/02
00-714-G	U.S. 09/830,620 Filed 8/15/01	Mirkin, Nguyen/ NANOPARTICLES WITH POLYMER SHELLS	PENDING
00-715-A	U.S. 09/760,500 Filed 1/12/01	Mirkin, Letsinger, Mucic, Storhoff, Elghanian, Taton; Garamella, Li/ METHOD OF ATTACHING OLIGONUCLEOTI DES TO NANOPARTICLES AND PRODUCTS PRODUCED THEREBY	ALLOWED
00-1085-A	U.S.S.N. 09/820,279 Filed 3/28/01	Mirkin,Letsinger, etc./ METHOD AND MATERIALS FOR ASSAYING BIOLOGICAL MATERIALS	ALLOWED
00-1085-G	U.S.S.N. 10/640,618 Filed 8/13/03	Mirkin,Letsinger, etc./ METHOD AND MATERIALS FOR ASSAYING BIOLOGICAL MATERIALS	
00-1086-A	U.S. 09/903,461 Filed 7/11/01	Letsinger, Garimella/ METHOD OF DETECTION BY ENHANCEMENT	U.S. Patent No. 6,602,669, Filed 8/5/03

ATTY	Serial No./		1 ago
Case No.	Filing Date	Inventors/Title	Status
		OF SILVER	
		STAINING	
00-1272-C	U.S.S.N.	Mirkin, Letsinger,	PENDING
	10/008,978	Mucic, Storhoff,	
i	Filed 12/7/01	Elghanian, Taton,	
		Garimella, Li, Park,	
		Lu/	
		NANOPARTICLES	
		HAVING	
		OLIGONUCLEOTI	
		DES ATTACHED	
		THERETO AND	
	7700771071071071071	USES THEREOF	
01-565-A	USSN 10/125,194	Mirkin, Nguygen,	PENDING
	Filed 4/18/02	Watson, Park/	
		OLIGONUCLEOTI	
		DE-MODIFIED	
		ROMP POLYMERS AND CO-	
		POLYMERS	
01-599-A	U.S.S.N.	Storhoff/NOVEL	PENDING
01-399-A	10/291,291	THIOL-BASED	FENDING
	Filed 11/08/02	METHOD FOR	
	1 11cd 11/06/02	ATTACHING	
		OLIGONUCLEOTI	
		DES TO	
		NANOPARTICLES	
01-661-A	U.S.S.N.	Mirkin, Cao, Jin/	PENDING
	10/034,451	DNA-MODIFIED	
	Filed 12/28/01	CORE-SHELL	
		AG/AU	
		NANOCRYSTALS	
01-661-C	U.S.S.N.	Mirkin, Cao, Jin/	PENDING
	10/153,483	DNA-MODIFIED	
	Filed 5/22/02	CORE-SHELL	
		AG/AU	
		NANOCRYSTALS	
01-661-E	U.S.S.N.	Mirkin, Cao, Jin/	PENDING
	10/397,579	DNA-MODIFIED	
	3/26/03	CORE-SHELL	
		AG/AU	
01 1777	HOON	NANOCRYSTALS	DEMONIC
01-1565-A	U.S.S.N.	Park, Taton,	PENDING
	10/266,983	Mirkin/ARRAY-	<u> </u>

ATTY	Serial No./		1 ag
Case No.	Filing Date	Inventors/Title	Status
	Filed 10/08/02	BASED	
		ELECTRICAL	
		DETECTION OF	
		DNA USING	
		NANOPARTICLE	
		PROBES	
01-1633-A	U.S.S.N.	Park, Taton,	PENDING
	10/266,983	Mirkin/NANOPARI	
	Filed 10/8/02	CLES HAVING	
		OLIGONUCLEOTI	
		DES ATTACHED	
		THERETO AND	
		USES THEREFOR	
01-1705-A	U.S.S.N.	Nam, Park,	PENDING
	10/108,211	Mirkin/BIO-	
	Filed 3/27/02	BARCODES	
,		BASED ON	
		OLIGONUCLEOTI	
		DE-MODIFIED	
02-338-B	TICCNI 10/172 429	NANOPARTICLES Cas. Lin. Nam.	DENIDING
02-338-B	USSN 10/172,428 Filed 6/14/02	Cao, Jin, Nam, Mirkin/MULTICHA	PENDING
	Filed 0/14/02	NNEL DETECTION	
		USING	
		NANOPARTICLE	
		PROBES WITH	:
		RAMAN	
		SPECTROSCOPIC	
		FINGERPRINTS	
02-338-C	10/431,341	Cao, Jin, Nam,	PENDING
	5/7/03	Mirkin/MULTICHA	- · -
		NNEL DETECTION	
		USING	
		NANOPARTICLE	
		PROBES WITH	
		RAMAN	
		SPECTROSCOPIC	
		FINGERPRINTS	

MAR 0 3 2004 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 00-713-i8)

In the Application of:

Chad A. Mirkin, et al.

Serial No.: 09/974,007

Filed: October 10, 2001

For: NANOPARTICLES HAVING

OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR

Examiner: Jezia Riley

Group Art Unit: 1637

Confirmation No.: 8209

RECEIVED

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

MAR 1 0 2004

SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, copies¹ of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

- 1. Heller, et al., U.S. Patent No. 4,966,143 issued 02/26/91
- 2. Kausch, et al., U.S. Patent No. 5,508,164 issued 04/16/96
- 3. Ewart, et al., U.S. Patent No. 5,922,537 issued 07/13/99
- 4. An, et al., U.S. Patent No. 5,972,615 issued 10/26/99

¹To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated there between; if no such English language equivalent is cited, then none is known to undersigned.

- 5. Blackburn, et al., U.S. Patent No. 6,264,825 issued 07/24/01
- 6. Yguerabide, et al., U.S. Patent No. 6,214,560 issued 04/10/01
- 7. International Patent WO 94/29484 published 12/22/94
- 8. International Patent WO 00/25136 published 05/04/00
- 9. Mohanty J., et al., "Pulsed laser excitation of phosphate stabilized silver nanoparticles," *Proc. Indian Acd.*, Vol. 112, No. 1, p. 63-72 (2000)
- 10. Nicewarner- Peńa S., et al., "Hybridization and Enzymatic Extension of Au Nanoparticle-Bound Oligonucleotides," *J. Am. Chem. Soc.*, Vol. 124, p. 7314-7323 (2002)
- 11. Whitesides G.M., et al., "Soft Lithography in Biology and Biochemistry," *Annu. Rev. Biomed. Eng.*, p. 335-373 (2001)

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course

of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: 5 1 - 05

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Suite 3200 Chicago, Illinois 60606

Telephone: (312) 913-0001 Facsimile: (312) 913-0002 Emily Miao

Registration No. 35,285

FORM PTO-1449 (Rev. 2-32)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No.

Serial No.

Sheet 1 of 1

09/974,007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

् ध्र

Applicant:

Chad A. Mirkin, et al.

Filing Date:

Group:

October 10, 2001

1637

RECEIVED

MAR 1 0 2004

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	4,996,143	02/26/91	Heller, et al.	435	6	04/13/90
	2.	5,508,164	04/16/96	Kausch, et al.	435	6	10/29/93
٠.	3.	5,922,537	07/13/99	Ewart, et al.	435	6	
	4.	5,972,615	10/26/99	An, et al.	435		11/8/96
	5.	6,264,825	07/24/01	Blackburn, et al.	-	6	01/21/98
	6.	6,214,560	04/10/01		205	777.5	06/23/99
	· · · · ·	0,214,300	04/10/01	Yguerabide, et al.	435	7.1	04/18/97

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country			Transia	tion
	7.	WO 94/29484	12/22/94	PCT	Class	Subclass	Yes	No
	8.	WO 00/25136	05/04/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

9.	Mohanty J., et al. "Pulsed laser excitation of phosphate stabilized silver nanoparticles," <i>Proc. Indian Acd. Sci.</i> , Vol. 112, No. 1, p. 63-72.
10	Peńa-Nicewarner S., et al., "Hybridization and Enzymatic Extension of Au Nanoparticle-Bound Oligonucleotides," <i>J. Am. Chem. Soc.</i> , Vol. 124, p. 7314-7323 (2002)
11.	Whitesides G.M., et al., "Soft Lithography in Biology and Biochemistry," <i>Annu. Rev. Biomed. Eng.</i> , p. 335-373 (2001)

EXAMINER

DATE CONSIDERED

XAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if it in conformance and not considered. Include copy of this form with next communication.



Hon. Commissioner of

S/N-09/974,007

Atty E

Patents and Trademarks

Re: Applicant - Mirkin, et al.

Case No. 00-713-i8

Nanoparticles Having Oligonucleotides Attached Thereto and Uses Therefor Date Mailed:

Sir:

Please place the Patent Office receipt stamp hereon and mail to acknowledge receipt of:

Seventh Supplemental Information Disclosure Statement

☑ U.S. PTO 1449 Form with copies of 11 references

Fee Enclosed \$ 180.00

Respectfully,
McDonnell Boehnen Hulbert & Berghoff
Attorney for Applicant

ZUEP4P42EEEV3

RECEIVED.

MAR 1 0 2004